JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

NASDAQ:JAZZ • IE00B4Q5ZN47

190.02 USD
+1.05 (+0.56%)
At close: Feb 27, 2026
190.02 USD
0 (0%)
After Hours: 2/27/2026, 8:12:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall JAZZ gets a fundamental rating of 4 out of 10. We evaluated JAZZ against 193 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. JAZZ is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • JAZZ had positive earnings in the past year.
  • JAZZ had a positive operating cash flow in the past year.
  • In multiple years JAZZ reported negative net income over the last 5 years.
  • JAZZ had a positive operating cash flow in 4 of the past 5 years.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • With a decent Return On Assets value of -3.24%, JAZZ is doing good in the industry, outperforming 75.13% of the companies in the same industry.
  • JAZZ has a Return On Equity of -9.31%. This is in the better half of the industry: JAZZ outperforms 75.65% of its industry peers.
  • The Return On Invested Capital of JAZZ (3.95%) is better than 82.90% of its industry peers.
  • JAZZ had an Average Return On Invested Capital over the past 3 years of 3.85%. This is significantly below the industry average of 12.93%.
  • The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROIC 3.95%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

  • In the last couple of years the Profit Margin of JAZZ has declined.
  • JAZZ has a Operating Margin of 10.92%. This is amongst the best in the industry. JAZZ outperforms 83.94% of its industry peers.
  • In the last couple of years the Operating Margin of JAZZ has declined.
  • JAZZ has a better Gross Margin (88.49%) than 91.19% of its industry peers.
  • In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 88.49%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • JAZZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • JAZZ has an Altman-Z score of 1.65. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
  • JAZZ's Altman-Z score of 1.65 is fine compared to the rest of the industry. JAZZ outperforms 60.62% of its industry peers.
  • JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.33, JAZZ belongs to the top of the industry, outperforming 85.49% of the companies in the same industry.
  • A Debt/Equity ratio of 1.09 is on the high side and indicates that JAZZ has dependencies on debt financing.
  • JAZZ's Debt to Equity ratio of 1.09 is on the low side compared to the rest of the industry. JAZZ is outperformed by 72.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Altman-Z 1.65
ROIC/WACC0.56
WACC7.11%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 1.65 indicates that JAZZ should not have too much problems paying its short term obligations.
  • JAZZ has a Current ratio of 1.65. This is in the lower half of the industry: JAZZ underperforms 66.84% of its industry peers.
  • JAZZ has a Quick Ratio of 1.44. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
  • JAZZ has a Quick ratio of 1.44. This is in the lower half of the industry: JAZZ underperforms 62.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.44
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for JAZZ have decreased strongly by -61.30% in the last year.
  • The Earnings Per Share has been decreasing by -8.04% on average over the past years.
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.96% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 7.37% on average per year.
EPS Next Y182.18%
EPS Next 2Y76.84%
EPS Next 3Y48.22%
EPS Next 5Y31.96%
Revenue Next Year6.22%
Revenue Next 2Y7.28%
Revenue Next 3Y7.68%
Revenue Next 5Y7.37%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.17, the valuation of JAZZ can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 80.31% of the companies listed in the same industry.
  • JAZZ is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 8.21 indicates a reasonable valuation of JAZZ.
  • Based on the Price/Forward Earnings ratio, JAZZ is valued cheaply inside the industry as 92.75% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of JAZZ to the average of the S&P500 Index (28.05), we can say JAZZ is valued rather cheaply.
Industry RankSector Rank
PE 23.17
Fwd PE 8.21
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 84.97% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaply inside the industry as 92.75% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.32
EV/EBITDA 12.41
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

  • JAZZ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of JAZZ may justify a higher PE ratio.
  • JAZZ's earnings are expected to grow with 48.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.13
PEG (5Y)N/A
EPS Next 2Y76.84%
EPS Next 3Y48.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for JAZZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (2/27/2026, 8:12:18 PM)

After market: 190.02 0 (0%)

190.02

+1.05 (+0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners104.02%
Inst Owner Change0.46%
Ins Owners2.48%
Ins Owner Change-0.22%
Market Cap11.55B
Revenue(TTM)N/A
Net Income(TTM)-368.48M
Analysts85.22
Price Target223.78 (17.77%)
Short Float %9.62%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.29%
PT rev (3m)15.46%
EPS NQ rev (1m)1.72%
EPS NQ rev (3m)1.53%
EPS NY rev (1m)1.18%
EPS NY rev (3m)54.77%
Revenue NQ rev (1m)0.76%
Revenue NQ rev (3m)1.02%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE 23.17
Fwd PE 8.21
P/S 2.78
P/FCF 9.32
P/OCF 8.3
P/B 2.92
P/tB N/A
EV/EBITDA 12.41
EPS(TTM)8.2
EY4.32%
EPS(NY)23.14
Fwd EY12.18%
FCF(TTM)20.39
FCFY10.73%
OCF(TTM)22.9
OCFY12.05%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)0.13
PEG (5Y)N/A
Graham Number109.64
Profitability
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROCE 5%
ROIC 3.95%
ROICexc 5.1%
ROICexgc 55.75%
OM 10.92%
PM (TTM) N/A
GM 88.49%
FCFM 29.8%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Debt/EBITDA 3.8
Cap/Depr 22.29%
Cap/Sales 3.68%
Interest Coverage 250
Cash Conversion 122.16%
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.44
Altman-Z 1.65
F-Score5
WACC7.11%
ROIC/WACC0.56
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
EPS Next Y182.18%
EPS Next 2Y76.84%
EPS Next 3Y48.22%
EPS Next 5Y31.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.09%
Revenue Next Year6.22%
Revenue Next 2Y7.28%
Revenue Next 3Y7.68%
Revenue Next 5Y7.37%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.5%
EBIT Next 3Y6.1%
EBIT Next 5Y6.52%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 8 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.


Can you provide the financial health for JAZZ stock?

The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 182.18% in the next year.